drugset / Trial / NCT03647982

Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers

NCT03647982

Phase 1 Completed 13 enrolled Medy-Tox
Non-randomizedParallel-groupDouble-blindTreatment

Summary

To determine the anhidrotic area and safety of MEDITOXIN

Timeline

Start
2018-03-20
Primary completion
2018-10-20
Completion
2018-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 1 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 3 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 5 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 10 iu Other